#ASH18: Leg­end Biotech — al­lied with J&J now — con­tin­ues to wow the crowd with their BC­MA CAR-T up­date. What will blue­bird say?

Back in the sum­mer of 2017, an un­known Chi­nese biotech called Leg­end jumped in­to AS­CO and dis­rupt­ed the rep blue­bird had care­ful­ly erect­ed for it­self as the break­away leader among com­pa­nies de­vel­op­ing a BC­MA-tar­get­ing CAR-T for mul­ti­ple myelo­ma, of­fer­ing up reg­u­lar looks at one of the in­dus­try’s top de­vel­op­ment pro­grams.

Leg­end of­fered star­tling proof-of-con­cept da­ta to sug­gest that they could leapfrog the pack and land among the top com­pa­nies pi­o­neer­ing the field. Soon af­ter J&J fol­lowed up with a rich $350 mil­lion cash up­front to part­ner with Leg­end, of­fer­ing their en­dorse­ment that the biotech was no fly-by-night pre­tender to the throne.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER